8-K: IFF to Sell Pharma Solutions Business to Roquette for Up to $2.85 Billion

International Flavors & Fragrances Inc. (IFF) has agreed to sell its Pharma Solutions business to Roquette for an enterprise value of up to $2.85 billion.

Summary

• International Flavors & Fragrances Inc. (IFF) has entered into a definitive agreement to sell its Pharma Solutions business to Roquette Frères S.A.
• The transaction is valued at up to $2.85 billion, representing an enterprise value to EBITDA multiple of approximately 13x.
• The Pharma Solutions business includes pharmaceutical excipients and a Global Specialty Solutions business.
• This sale is part of IFF's strategy to optimize its portfolio and reduce debt leverage to 3.0x or below.
• The Pharma Solutions business generated approximately $1 billion in revenue in 2023 and has around 1100 employees.
• The deal is expected to close in the first half of 2025, subject to regulatory approvals and other closing conditions.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strategic divestiture, debt reduction, and focus on core growth. However, there are risks associated with the transaction closing and the impact on IFF's overall business.

Positives

• The sale of Pharma Solutions is a significant step in IFF's portfolio optimization strategy.
• The transaction will help IFF reduce its debt leverage to 3.0x or below.
• The sale will allow IFF to increase focus on core drivers of long-term profitable growth.
• The deal is expected to provide value for IFF shareholders.
• Roquette is a strong partner for the Pharma Solutions business, which is expected to expand its industry leadership.

Risks

• The transaction is subject to regulatory approvals and customary closing conditions, which could delay or prevent the sale.
• There is a risk that the transaction may not close in the expected timeframe of the first half of 2025.
• The sale of a significant business unit could impact IFF's overall revenue and market position.

Future Outlook

The sale of Pharma Solutions is expected to enable IFF to reduce debt leverage and focus on core growth drivers. The transaction is expected to close in the first half of 2025.

Management Comments

• IFF CEO Erik Fyrwald stated that the agreement with Roquette will support Pharma Solutions next chapter of growth.
• Erik Fyrwald also noted that the sale is an important step in their portfolio optimization strategy and commitment to reducing debt leverage.
• Pierre Courduroux, CEO of Roquette, expressed excitement about the partnership with the Pharma Solutions team at IFF.

Industry Context

This divestiture reflects a trend of companies focusing on core businesses and divesting non-core assets. The pharmaceutical excipients market is competitive, and this transaction positions Roquette as a major player in the space.

Comparison to Industry Standards

• The 13x EBITDA multiple is within the range of recent transactions in the specialty chemicals and pharmaceutical ingredients sector.
• Comparable companies in the pharmaceutical excipients market include Ashland and DuPont, which have also engaged in strategic divestitures and acquisitions to optimize their portfolios.
• The $2.85 billion valuation is significant, reflecting the scale and profitability of IFF's Pharma Solutions business.

Stakeholder Impact

• Shareholders are expected to benefit from the debt reduction and increased focus on core growth.
• Employees of the Pharma Solutions business will transition to Roquette.
• Customers of Pharma Solutions are expected to experience continuity of service under Roquette's ownership.
• IFF will be able to focus on its core businesses in food, beverage, scent, health and biosciences.

Next Steps

• IFF and Roquette will work towards satisfying regulatory approvals and other closing conditions.
• The transaction is expected to close in the first half of 2025.

Key Dates

Keywords

Pharma Solutions, Roquette, Divestiture, Pharmaceutical Excipients, Debt Reduction, Portfolio Optimization, Mergers and Acquisitions, IFF